Atlas Trials

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Clinical trial NCT03975036 · UNKNOWN

Trial details

NCT number
NCT03975036
Sponsor
Henan Cancer Hospital
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Advanced Solid Tumor
Start date
2019-04-08
Primary completion
2020-06-08
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.